Question 2: Is there a role for Montelukast in the management of viral-induced wheeze in preschool children?

Burman, Alisha

doi:10.1136/archdischild-2018-314905

Cited by 3 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are many studies in the literature evaluating the use of continuous or intermittent LTRA in the treatment of wheezing in children compared to placebo [12,[18][19][20][21][22]. In these studies carried out until present, the eff ect of montelukast in the treatment of wheezing has been reported as eff ective in some studies and not eff ective in others [13][14][15]. Montelukast Table 3: The number of before treatment and 1 st evaluation attacks in patients with negative and positive mAPI scores.…”

Section: Discussionmentioning

confidence: 99%

“…After all, LTRA's have signifi cant antiinfl ammatory and bronchoprotective eff ects [4,7,12]. However, the results of studies investigating the eff ect of the use of LTRAs as maintenance or intermittent therapy on the frequency and severity of attacks in children with EVW are contradictory [13][14][15]. The aim of this study is to evaluate the eff ectiveness of montelukast in pediatric patients with episodic wheezing and API negative.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Effect of Montelukast in Children with Asthma Predictive Index Negative Episodic Viral Wheezing

Aydogdu¹,

Fidan²

2023

J Biomed Res Environ Sci

View full text Add to dashboard Cite

Background: The effectiveness of montelukast for wheezing in young children is not clear. We aimed to evaluate whether the use of montelukast in the treatment of wheezing affects the number of attacks in children aged 1 to 6 years. Methods: This is a single center study. It was conducted between August 2019-2020. Children with aged 0-6 years old with a wheezing complaint who applied to the pediatric allergy and immunology outpatient clinic were included in the study. Modified asthma predictive index of the patients were evaluated. It was classified as Episodic Viral Wheezing (EVW) or Multiple Trigger Wheezing (MTW) based on the type of wheezing. Montelukast treatment was started and the number of attacks was checked during five months. Results: The total of 141 children who applied with wheezing complaints were included in the study. The majority of the patients were boys (n = 99). The mean age of the children was 4.2 ± 1.5 years. The median number of attacks before treatment was 2 (2-3). In 2.8% of the patients, eczema, in 12.8% of them, rhinitis and in 26.7% of them, elevated eosinophils were detected. IgE levels were 148.25 ± 279.20 IU/mL. According to the number of attacks before treatment, there was a significant decrease in the number of attacks in followup (p < 0.001). Conclusion: In this study, montelukast has been shown to reduce the number of EVW attacks and we believe montelukast may be a potential treatment option for EVW in preschool children.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The Effect of Montelukast in Children with Asthma Predictive Index Negative Episodic Viral Wheezing

Aydogdu¹,

Fidan²

2023

J Biomed Res Environ Sci

View full text Add to dashboard Cite

show abstract

“…12,[18][19][20][21][22] In these studies carried out until present, the effect of montelukast in the treatment of wheezing has been reported as effective in some studies and not effective in others. [13][14][15] Montelukast has been shown to have positive effects on asthma symptoms in the study of Barbara Knorr et al 23 In the study of Bisgaard et al in year 2005, it was found that maintenance montelukast treatment decreased the rate of exacerbation compared to placebo. It has been shown to be effective in controlling wheezing attacks triggered by viral infections, especially in children aged 2-5 years.…”

Section: Discussionmentioning

confidence: 99%

“…4,7,12 However, the results of studies investigating the effect of the use of LTRAs as maintenance or intermittent therapy on the frequency and severity of attacks in children with EVW are contradictory. [13][14][15] The aim of this study is to evaluate the effectiveness of montelukast in pediatric patients with episodic wheezing and API negative.…”

Section: Introductionmentioning

confidence: 99%

The effect of montelukast in children with asthma predictive ındex negative episodic viral wheezing

Aydoğdu¹,

Fidan

2021

Preprint

View full text Add to dashboard Cite

Background: The effectiveness of montelukast for wheezing in young children is not clear. We aimed to evaluate whether the use of montelukast in the treatment of wheezing affects the number of attacks in children aged 1 to 6 years. Methods: This is a single center study. It was conducted between August 2019 – 2020. Children with aged 0-6 years old with a wheezing complaint who applied to the pediatric allergy and immunology outpatient clinic were included in the study. Modified asthma predictive index of the patients were evaluated. It was classified as episodic viral wheezing (EVW) or multiple trigger wheezing (MTW) based on the type of wheezing. Montelukast treatment was started and the number of attacks was checked. Results: The total of 141 children who applied with wheezing complaints were included in the study. The majority of the patients were boys (n=99). The mean age of the children was 4.2 ± 1.5 years. The median number of attacks before treatment was 2 (2-3). In 2.8% of the patients, eczema, in 12.8% of them, rhinitis and in 26.7% of them, elevated eosinophils were detected. IgE levels were 148.25 ± 279.20 IU/mL. According to the number of attacks before treatment, there was a significant decrease in the number of attacks in the control (p <0.001). Conclusion: In this study, montelukast has been shown to reduce the number of EVW attacks and we believe montelukast may be a potential treatment option for EVW in preschool children.

show abstract

Clinical efficacy of antileukotriene therapy in children with acute bronchitis

Мизерницкий

Гаймоленко

Markovskaya

et al. 2023

Ross. vestn. perinatol. pediatr.

View full text Add to dashboard Cite

Recurrent episodes of bronchial obstruction in preschool children are one of the important risk factors for the development of bronchial asthma.Purpose. The study aimed at investigating the clinical and immunological characteristics of children with acute bronchitis and to determine the clinical effectiveness of course anti-inflammatory therapy.Material and methods. The study was a single-center prospective cohort, including 1–5-year-old patients with acute bronchitis (main group, n = 109): a group with acute simple bronchitis (n = 34) and acute obstructive bronchitis (n = 75). Reference group: children of health group 2 (n = 29). Clinical and anamnestic and laboratory methods were used. Patients with a positive API (Asthma Predictive Index) were administered montelukast at a dose of 4 mg orally once a day for 3 months (control points at 1 and 3 months), reference patients received symptomatic therapy for respiratory infection. The end point of the study is the absence of bronchial obstruction. The effectiveness of the use of Montelukast was evaluated by calculating the clinical index, efficiency coefficient. Results. A statistically significant predominance of intoxication symptoms was found in patients with acute simple bronchitis (p = 0.02), signs of respiratory failure (p < 0.001), and peripheral eosinophilia — in children with acute obstructive bronchitis (p = 0.02). In etiology, rhinovirus significantly prevailed in patients with bronchial obstruction, and RS virus prevailed in patients with acute simple bronchitis (p = 0.02). The cytokine profile of patients with acute obstructive bronchitis is characterized by a decrease in the levels of macrophage inflammatory proteins (p = 0.01) and IL-8 (p = 0.048). A prolonged course of montelukast in children with a positive API significantly reduces the severity of subsequent acute respiratory infections, reduces the frequency of bronchial obstruction and the risk of bronchial asthma (p < 0.001).Conclusion. Evaluation of the results of montelukast therapy demonstrated clinical efficacy in patients with a positive API index.

show abstract

Question 2: Is there a role for Montelukast in the management of viral-induced wheeze in preschool children?

Cited by 3 publications

References 6 publications

The Effect of Montelukast in Children with Asthma Predictive Index Negative Episodic Viral Wheezing

The Effect of Montelukast in Children with Asthma Predictive Index Negative Episodic Viral Wheezing

The effect of montelukast in children with asthma predictive ındex negative episodic viral wheezing

Clinical efficacy of antileukotriene therapy in children with acute bronchitis

Contact Info

Product

Resources

About